Development of HER2-specific Humanized Antibody Herceptin (Trastuzumab).

Folia Pharmacologica Japonica - Japan
doi 10.1254/fpj.122.504
Full Text
Abstract

Available in full text

Categories
Pharmacology
Date
Authors
Publisher

Japanese Pharmacological Society

Related search

Trastuzumab (Herceptin)

American Journal of Neuroradiology
MedicineNuclear MedicineNeurologyImagingRadiology
2011English

Pharmacoeconomic Study of Herceptin® (Trastuzumab) for Breast Cancer Patients

Pharmacoeconomics: theory and practice
2014English

The Latest Research and Development Into the Antibody–Drug Conjugate, [Fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy

Chemical and Pharmaceutical Bulletin
MedicineDrug DiscoveryChemistry
2019English

Subcutaneous Administration of Rituximab (MabThera) and Trastuzumab (Herceptin) Using Hyaluronidase

British Journal of Cancer
Cancer ResearchOncology
2013English

Direct Detection of Herceptin/Trastuzumab Binding on Breast Tissue Sections

Journal of Histochemistry and Cytochemistry
AnatomyHistology
2006English

Safety of Trastuzumab (Herceptin®) During Pregnancy: Two Case Reports

Cases Journal
2009English

Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Lapatinib Enhances Trastuzumab-Mediated Antibody-Dependent Cellular Cytotoxicity via Upregulation of HER2 in Malignant Mesothelioma Cells

Oncology Reports
MedicineCancer ResearchOncology
2015English

Pharmacological Blockade of Fatty Acid Synthase (FASN) Reverses Acquired Autoresistance to Trastuzumab (Herceptin™) by Transcriptionally Inhibiting ‘HER2 Super-Expression’ Occurring in High-Dose Trastuzumab-Conditioned SKBR3/Tzb100 Breast Cancer Cells

International Journal of Oncology
Cancer ResearchOncology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy